Clients must have absolutely recovered with the acute poisonous consequences of all prior anti-cancer therapy and should fulfill the next minimum period from prior anti-cancer directed therapy ahead of enrollment. Experimental: Dose expansion_sub-populace 2_lower dose of niraparib MTDs and/or prospect RP2Ds for elimusertib used in combination with niraparib at a https://pearlh544sdo7.elbloglibre.com/profile